Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
2.260
-0.020 (-0.88%)
At close: Dec 5, 2025, 4:00 PM EST
2.260
0.00 (0.00%)
After-hours: Dec 5, 2025, 4:00 PM EST
Spero Therapeutics Revenue
Spero Therapeutics had revenue of $5.44M in the quarter ending September 30, 2025, a decrease of -59.60%. This brings the company's revenue in the last twelve months to $40.55M, down -61.91% year-over-year. In the year 2024, Spero Therapeutics had annual revenue of $47.98M, down -53.77%.
Revenue (ttm)
$40.55M
Revenue Growth
-61.91%
P/S Ratio
3.12
Revenue / Employee
$1,267,156
Employees
32
Market Cap
127.61M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 47.98M | -55.80M | -53.77% |
| Dec 31, 2023 | 103.78M | 50.27M | 93.95% |
| Dec 31, 2022 | 53.51M | 35.25M | 193.10% |
| Dec 31, 2021 | 18.26M | 8.93M | 95.67% |
| Dec 31, 2020 | 9.33M | -8.82M | -48.59% |
| Dec 31, 2019 | 18.15M | 14.18M | 357.56% |
| Dec 31, 2018 | 3.97M | 1.99M | 100.40% |
| Dec 31, 2017 | 1.98M | 1.64M | 490.75% |
| Dec 31, 2016 | 335.00K | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SPRO News
- 7 days ago - Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 22 days ago - Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update - GlobeNewsWire
- 4 weeks ago - Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025 - GlobeNewsWire
- 6 weeks ago - PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs) - GlobeNewsWire
- 7 weeks ago - Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek - GlobeNewsWire
- 4 months ago - Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update - GlobeNewsWire
- 4 months ago - Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025 - GlobeNewsWire